LOS ALTOS, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024 at 10:30 a.m. ET in New York, NY.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.
Investor Contact:
[email protected]
(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
- FORD INVESTOR DEADLINE: Ford Motor Company Investors that Lost Money are Reminded to Contact BFA Law by October 7 Court Deadline in Class Action Lawsuit (NYSE:F) - September 13, 2024
- SMCI INVESTOR DEADLINE: Super Micro Computer, Inc. Investors that Lost Money are Reminded to Contact BFA Law by October 29 Court Deadline in Class Action Lawsuit (Nasdaq:SMCI) - September 13, 2024
- EXTR INVESTOR DEADLINE: Extreme Networks, Inc. Investors that Lost Money are Reminded to Contact BFA Law by October 15 Court Deadline in Class Action Lawsuit (Nasdaq:EXTR) - September 13, 2024
